Intellia Therapeutics, Inc. (NTLA) vs Septerna Inc (SEPN)
A side-by-side comparison of Intellia Therapeutics, Inc. and Septerna Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NTLA
Intellia Therapeutics, Inc.
$12.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SEPN
Septerna Inc
$35.67HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NTLA vs SEPN
growth of $100 · dividends reinvested · last 2yNTLA -36.1% (-20.0%/yr)SEPN +77.0% (+33.0%/yr)SEPN compounded faster over this window
NTLA SEPN
NTLA vs SEPN: by the numbers
- •NTLA is the larger company ($1.73B vs $1.61B market cap).
- •Both run net losses; SEPN's is the smaller (-24.51% vs -672.16% net margin).
Metrics side by side
Valuation
| Metric | NTLA | SEPN |
|---|---|---|
| P/S ratio | 29.05 | 16.26 |
| P/B ratio | 2.38 | 4.16 |
| FCF yield | N/A | 6.54% |
Profitability
| Metric | NTLA | SEPN |
|---|---|---|
| Gross margin | 76.47% | 99.57% |
| Operating margin | -651.67% | -175.83% |
| Net margin | -672.16% | -24.51% |
| ROE | -54.96% | -6.27% |
| ROIC | -54.45% | -8.93% |
Growth (annualized)
| Metric | NTLA | SEPN |
|---|---|---|
| Revenue CAGR (5Y) | 7.31% | N/A |
| Total return CAGR (5Y) | -37.13% | N/A |
Go deeper
Dig into the metrics
Intellia Therapeutics ROESepterna ROEIntellia Therapeutics operating marginSepterna operating marginIntellia Therapeutics revenue growthSepterna revenue growthIntellia Therapeutics free cash flowSepterna free cash flow
Intellia Therapeutics & Septerna appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.